A combination of daunorubicin, cytarabineand imatinib mesylate for patients with de novo Philadelphia positive acute myeloblastic leukemia and myeloid blast crisis CML : Results of the AFR01 dose escalating study

作者:Rousselot P H; Deau B; Nicolini F; Guilhot J; Huguet F; Rio B; Guerci A; Legros L; Pautas C; Rea D; Raffoux E; Berthou C; Guyotat D; Cony Makhoul P; Gardembas M; Castaigne S; Michallet M; Mahon F X; Guilhot F; Rousselot P
来源:12th Congress of the European-Hematology-Association, 2007-06-07 to 2007-06-10.